A system and method for monitoring the use of aerosolized medicine

Abstract

The present invention provides a system and method for monitoring the use of atomized drugs. A data acquisition unit is used to acquire basic data of a user, and acquire a standard deposition efficiency range of a drug to be atomized based on the basic data; a respiratory model construction unit is used to acquire the respiratory data of the user, and construct a respiratory model according to the respiratory data of the user; an initial atomization path construction unit is used to output the movement process of drugs to be atomized with different particle sizes in the respiratory model as a plurality of initial atomization paths; an optimization unit is used to optimize the initial atomization path based on the deposition efficiency being within the standard deposition efficiency range by using a sparrow search algorithm, and obtain an optimal atomization path; an atomization working unit is used to atomize the drug to be atomized based on the particle size of the drug to be atomized in the optimal atomization path, and deliver it to the user, so that the drug particle size that is most suitable for the user can be found, and when atomization treatment is performed with this particle size, targeted treatment can be achieved and the treatment effect can be improved.

Description

Technical Field

[0001] The present invention relates to the technical field of atomized medicine application, and in particular to a system and method for monitoring the use of atomized medicine. Background Art

[0002] Nebulizer therapy refers to the use of a nebulizer to convert drugs into tiny droplets, which the user can directly inhale into the respiratory tract and lungs, thereby achieving rapid drug action and local high concentration distribution, improving treatment effects and reducing systemic adverse reactions. With the increasing popularity of nebulizer therapy, its accuracy and effectiveness have become key issues. The current efficacy of nebulized drugs depends to a large extent on the deposition location and efficiency of drug particles in the respiratory tract. However, due to the complex structure of the human respiratory tract and differences in breathing patterns among individuals, the movement and deposition process of drug particles in the respiratory tract are affected by the interaction of multiple factors. Traditional nebulizer methods lack effective means to monitor the deposition path, deposition efficiency and distribution of drug particles in different respiratory areas in real time, resulting in the inability to adjust the nebulizer plan according to actual conditions and to ensure that the drug can reach the lesion site and exert its effect to the greatest extent. Summary of the invention

[0003] In view of this, the present invention proposes a system and method for monitoring the use of aerosolized drugs, which can obtain the aerosolized drug particle size that is most suitable for the user to perform aerosol therapy and achieve targeted treatment.

[0004] The technical solution of the present invention is achieved in this way:

[0005] A method for monitoring the use of aerosolized drugs, comprising the following steps:

[0006] Step S1, obtaining basic data of the user, and obtaining a standard deposition efficiency range of the drug to be atomized based on the basic data;

[0007] Step S2: Acquire the user's respiratory tract data, and construct a respiratory tract model according to the user's respiratory tract data;

[0008] Step S3, outputting the movement process of the to-be-atomized drugs of different particle sizes in the respiratory tract model as a plurality of initial atomization paths;

[0009] Step S4, using a sparrow search algorithm to optimize the initial atomization path based on the deposition efficiency being within the standard deposition efficiency range, and obtaining the optimal atomization path;

[0010] Step S5: atomize the medicine to be atomized based on the particle size of the medicine to be atomized in the optimal atomization path, and deliver it to the user.

[0011] Preferably, the specific steps of step S1 include:

[0012] Step S11, extracting basic information of the user, the basic information including height, weight, age, medical history and allergy history;

[0013] Step S12, obtaining the type of medicine to be atomized suitable for the user according to the basic information of the user;

[0014] Step S13, obtaining a standard deposition efficiency range from the instructions for use of the drug to be atomized;

[0015] Preferably, when obtaining the type of medicine to be atomized, step S12 inputs the basic information of the user into a trained deep learning network, which is processed by the deep learning network to obtain the type of medicine to be atomized suitable for the user.

[0016] Preferably, the specific steps of step S2 include:

[0017] Step S21, obtaining a chest CT scan image of the user, preprocessing the CT scan image, and obtaining a respiratory tract tomographic anatomical image;

[0018] Step S22, using three-dimensional reconstruction software to convert the anatomical image into a three-dimensional geometric model;

[0019] Step S23, performing a pulmonary ventilation function test and a respiratory impedance test on the user, and constructing an airflow field model after collecting respiratory function data;

[0020] Step S24, superimposing the airflow field model onto the three-dimensional geometric model to obtain a respiratory tract model;

[0021] Preferably, after obtaining the three-dimensional geometric model, a surface mesh simplification technique is used to reduce the number of faces and nodes of the three-dimensional geometric model.

[0022] Preferably, the specific steps of step S3 include:

[0023] Step S31, preliminarily determining the particle size range according to the physical and chemical properties of the drug to be atomized;

[0024] Step S32, obtaining the atomizer device information to be used, and narrowing the particle size range based on the atomizer device information;

[0025] Step S33, randomly selecting a particle size from the particle size range, and inputting the drug of the particle size into the respiratory tract model;

[0026] Step S34, record the movement path of the drug in the respiratory tract model and output it as an initial atomization path, repeat steps S33-S34, and obtain several initial atomization paths.

[0027] Preferably, before the drug moves in the respiratory tract model, after applying airflow drag, gravity and Brownian force to the respiratory tract model, the movement path of the drug in the respiratory tract model is recorded.

[0028] Preferably, the specific steps of step S4 include:

[0029] Step S41, initializing the sparrow population, and setting the number of iterations to the number of initial atomization paths;

[0030] Step S42, randomly selecting an initial atomization path, and calculating the fitness value of the sparrow based on the deposition efficiency being within the standard deposition efficiency range;

[0031] Step S43, selecting another initial atomization path, calculating the fitness value, comparing it with the fitness value calculated last time, and retaining the initial atomization path with a larger fitness value;

[0032] Step S44: perform iterative calculation and output the initial atomization path with the largest fitness value as the optimal atomization path.

[0033] Preferably, in step S5, when delivering the atomized drug to the user, the user's breathing frequency, inhalation depth and exhalation time are monitored in real time, and after updating the respiratory model based on the real-time monitoring data, the initial atomization path and the optimal atomization path are reacquired, and the atomization state is updated according to the drug particle size in the latest optimal atomization path.

[0034] A system for monitoring the use of aerosolized medicine, comprising:

[0035] A data acquisition unit, used to acquire basic data of a user, and acquire a standard deposition efficiency range of the drug to be atomized based on the basic data;

[0036] A respiratory tract model building unit, used to obtain the user's respiratory tract data and build a respiratory tract model according to the user's respiratory tract data;

[0037] An initial atomization path construction unit is used to output the movement process of the atomized drugs with different particle sizes in the respiratory tract model as a number of initial atomization paths;

[0038] An optimization unit, used for optimizing the initial atomization path by using a sparrow search algorithm based on the deposition efficiency being within a standard deposition efficiency range, and obtaining an optimal atomization path;

[0039] An atomization working unit, used for atomizing the atomized medicine based on the particle size of the atomized medicine in the optimal atomization path, and delivering the atomized medicine to the user;

[0040] The initial atomization path construction unit is respectively connected with the data acquisition unit, the respiratory tract model construction unit and the optimization unit, and the optimization unit is respectively connected with the data acquisition unit and the atomization working unit.

[0041] Compared with the prior art, the present invention has the following beneficial effects:

[0042] The present invention provides a system and method for monitoring the use of aerosolized drugs. After acquiring the basic data of the user, the aerosolized drugs used to treat the user can be obtained, and the standard deposition efficiency range can be determined from the aerosolized drugs. After constructing a respiratory model based on the respiratory data of the user, aerosolized drugs of different particle sizes can be input into the respiratory model to construct multiple initial aerosol paths. Then, the sparrow optimization algorithm is used to optimize the initial aerosol paths. The optimization goal is to find the initial aerosol path whose deposition efficiency is within the standard deposition efficiency range, and output it as the optimal aerosol path. Finally, aerosol treatment can be performed according to the optimal aerosol path, and the aerosolized drugs can be delivered to the user, so as to achieve targeted treatment and improve the treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only preferred embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0044] Figure 1 The present invention is a flow chart of a method for monitoring the use of aerosolized drugs.

[0045] Figure 2 This is a flow chart of step S1 of a method for monitoring the use of aerosolized medicine according to the present invention.

[0046] Figure 3 This is a flow chart of step S2 of a method for monitoring the use of aerosolized medicine according to the present invention.

[0047] Figure 4 This is a flow chart of step S3 of a method for monitoring the use of aerosolized medicine according to the present invention.

[0048] Figure 5 This is a flow chart of step S4 of a method for monitoring the use of aerosolized medicine according to the present invention.

[0049] Figure 6 The schematic diagram of a system for monitoring the use of aerosolized drugs according to the present invention.

[0050] In the figure, 1. Data acquisition unit; 2. Respiratory model building unit; 3. Initial atomization path building unit; 4. Optimization unit; 5. Atomization working unit. DETAILED DESCRIPTION

[0051] In order to better understand the technical content of the present invention, a specific embodiment is provided below, and the present invention is further described in conjunction with the accompanying drawings.

[0052] See also Figures 1 to 5 The present invention provides a method for monitoring the use of aerosolized drugs, comprising the following steps:

[0053] Step S1, obtaining basic data of the user, and obtaining a standard deposition efficiency range of the drug to be atomized based on the basic data;

[0054] Step S2: Acquire the user's respiratory tract data, and construct a respiratory tract model according to the user's respiratory tract data;

[0055] Step S3, outputting the movement process of the to-be-atomized drugs of different particle sizes in the respiratory tract model as a plurality of initial atomization paths;

[0056] Step S4, using a sparrow search algorithm to optimize the initial atomization path based on the deposition efficiency being within the standard deposition efficiency range, and obtaining the optimal atomization path;

[0057] Step S5: atomize the medicine to be atomized based on the particle size of the medicine to be atomized in the optimal atomization path, and deliver it to the user.

[0058] A method for monitoring the use of aerosolized drugs of the present invention is applied in drug treatment. After first obtaining the basic data of the user, the drug used to treat the user's disease can be found according to the basic data of the user, the found drug is output as the drug to be aerosolized, and the standard deposition efficiency range is obtained according to the instructions for use of the drug to be aerosolized and the basic data of the user, wherein the standard deposition efficiency range refers to the range that can play the maximum effect when applied in the user's body, and different users have different standard deposition efficiency ranges due to differences in body shape, age, etc. and different illness durations. After obtaining the standard deposition efficiency range, the user's respiratory tract data is collected, and then a respiratory tract model is constructed according to the respiratory tract data. The respiratory tract in the user's body is simulated by the respiratory tract model, and the respiratory tract model can be used to analyze the drug to be aerosolized in the respiratory tract. The transportation and deposition conditions in the respiratory tract. When the nebulized drug is atomized into drugs of different particle sizes, the transportation distance and deposition position in the respiratory tract are also different. Therefore, the drugs to be atomized are divided into several drugs of different particle sizes according to their levels and then input into the respiratory tract model. The movement process of the drug in the respiratory tract model is regarded as its initial atomization path, and drugs of different particle sizes will form multiple initial atomization paths. Finally, the sparrow search algorithm is used to optimize the initial atomization path to obtain the optimal atomization path. When performing atomization treatment, the user can choose the drug particle size in the optimal atomization path to atomize the drug. When atomizing the drug according to the particle size, the deposition efficiency will be in line with the standard deposition efficiency range of the drug to be atomized by the user, so that targeted treatment can be given to the user, thereby improving the efficiency of the user's treatment.

[0059] Preferably, the specific steps of step S1 include:

[0060] Step S11, extracting basic information of the user, the basic information including height, weight, age, medical history and allergy history;

[0061] Step S12, obtaining the type of medicine to be atomized suitable for the user according to the basic information of the user;

[0062] Step S13, obtaining a standard deposition efficiency range from the instructions for use of the drug to be atomized;

[0063] Basic information such as the user's age, gender, height, and weight can be collected through the medical record system or by directly asking the user. This basic information can be used to preliminarily assess the user's physical condition and the approximate range of respiratory function. For example, there are obvious differences in the size of the respiratory tract and the breathing pattern between children and adults. Age information is helpful for the preliminary selection of subsequent models. Height and weight are also related to indicators such as lung capacity, which in turn affect the deposition of drugs in the respiratory tract.

[0064] Medical records can be used to understand the user's medical history in detail, especially respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, etc. For users with asthma, it is also necessary to understand the severity of asthma, frequency of attacks, triggering factors, etc. The user's medical history and allergy history can be used to find the type of drug to be atomized for treatment. Finally, the standard deposition efficiency range can be obtained through the instructions for use of the drug to be atomized and combined with the user's basic data. If the atomization deposition efficiency is within the standard deposition efficiency range, the user's absorption of the drug will be better, thereby improving the treatment effect of the disease.

[0065] Preferably, when obtaining the type of medicine to be atomized, step S12 inputs the basic information of the user into a trained deep learning network, which is processed by the deep learning network to obtain the type of medicine to be atomized suitable for the user.

[0066] As for how to obtain the type of medicine to be atomized, the present invention adopts a deep learning network to achieve it. The deep learning network is trained by a large amount of historical data. The accuracy of the deep learning network can be tested after the training is completed. After the accuracy reaches the preset requirement, the training of the deep learning network can be stopped, and the basic information of the user can be input into the deep learning network. The deep learning network will identify and obtain the type of medicine to be atomized suitable for the user.

[0067] Preferably, the specific steps of step S2 include:

[0068] Step S21, obtaining a chest CT scan image of the user, preprocessing the CT scan image, and obtaining a respiratory tract tomographic anatomical image;

[0069] Step S22, using three-dimensional reconstruction software to convert the anatomical image into a three-dimensional geometric model, and using surface mesh simplification technology to reduce the number of faces and nodes of the three-dimensional geometric model;

[0070] Step S23, performing a pulmonary ventilation function test and a respiratory impedance test on the user, and constructing an airflow field model after collecting respiratory function data;

[0071] Step S24: superimpose the airflow field model onto the three-dimensional geometric model to obtain a respiratory tract model.

[0072] CT scanning can provide high-resolution sectional images, clearly showing the anatomical structure of the respiratory tract, including the morphology, diameter, wall thickness, and relationship with surrounding tissues of the trachea and bronchial branches at all levels. After preprocessing such as image segmentation, the respiratory tract structure can be separated from the surrounding lung tissue, bones, and other backgrounds, and a sectional anatomical image of the respiratory tract can be obtained. Then, the sectional anatomical image can be converted into a three-dimensional geometric model using layer-by-layer contour extraction and three-dimensional reconstruction software such as Mimics. Since the three-dimensional geometric model contains a large number of details and complex structures, it may consume huge computing resources during subsequent numerical simulations. Therefore, it is necessary to properly optimize and simplify the constructed geometric model. The present invention adopts surface mesh simplification technology to reduce the number of faces and nodes of the model without affecting the key features of the model and the simulation accuracy. For example, for small bronchial branches that are far away from the main area of ​​drug deposition or have little effect on airflow and drug particle movement, appropriate merging or simplification can be performed, while retaining the fine structure of the bronchial trunk and main branches to balance the accuracy and computational efficiency of the model.

[0073] When drugs are delivered in the respiratory tract, they will also be affected by the user's breathing process. Therefore, it is necessary to test the user's respiratory function, including pulmonary ventilation function test and respiratory impedance measurement. The pulmonary ventilation function test includes the measurement of indicators such as forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and peak expiratory flow rate (PEF). These data reflect the patient's overall respiratory power and ventilation capacity, and respiratory impedance measurement can further measure parameters such as resistance, compliance and inertia during the patient's breathing, which can more comprehensively describe the mechanical properties of the respiratory tract, especially in the evaluation of small airway function. After the respiratory test, the airflow inlet and outlet conditions and the boundary conditions of the respiratory tract wall can be determined according to the respiratory function test data. Then, the computational fluid dynamics (CFD) method is used to select a suitable turbulence model to describe the airflow flow characteristics in the respiratory tract, and an airflow field model is constructed. The airflow field model is then superimposed on the three-dimensional geometric model to finally form a respiratory model containing an airflow field, which can simulate the respiratory tract of a real human body to ensure the accuracy of subsequent deposition efficiency calculations.

[0074] Preferably, the specific steps of step S3 include:

[0075] Step S31, preliminarily determining the particle size range according to the physical and chemical properties of the drug to be atomized;

[0076] Step S32, obtaining the atomizer device information to be used, and narrowing the particle size range based on the atomizer device information;

[0077] Step S33, randomly selecting a particle size from the particle size range, and inputting the drug of the particle size into the respiratory tract model;

[0078] Step S34: After applying airflow drag, gravity and Brownian force to the respiratory tract model, the movement path of the drug in the respiratory tract model is recorded and output as an initial atomization path, and steps S33-S34 are repeated to obtain several initial atomization paths.

[0079] Analyze the physical and chemical properties of the drug to be atomized, including factors such as the solubility, stability and expected site of action of the drug, to preliminarily determine the appropriate particle size range. At the same time, obtain the information of the nebulizer equipment in use. Different nebulizers (such as ultrasonic nebulizers, compressed air nebulizers, etc.) produce different drug particle size distributions. According to the nebulizer equipment information, the particle size range can be narrowed down and the final drug particle size range can be obtained. Then, the particle size range is reasonably graded to obtain a variety of drugs with different particle sizes. Then, randomly select a drug with one particle size and input it into the respiratory tract. In the respiratory tract model, a force field is applied to the respiratory tract model to simulate the force conditions of drug particles. The forces on the drug in the respiratory tract include airflow drag, gravity, and Brownian force. The drug will move along the airflow direction in the respiratory tract and its trajectory will change due to the action of various forces. When the drug particles collide with the respiratory tract wall or reach the alveolar area and other predetermined deposition conditions, the simulation can be stopped. At this time, the movement path of the drug can be recorded and output as the initial atomization path. Then, the movement of drugs with different particle sizes in the respiratory tract model can be simulated repeatedly to obtain several initial atomization paths.

[0080] Preferably, the specific steps of step S4 include:

[0081] Step S41, initializing the sparrow population, and setting the number of iterations to the number of initial atomization paths;

[0082] Step S42, randomly selecting an initial atomization path, and calculating the fitness value of the sparrow based on the deposition efficiency being within the standard deposition efficiency range;

[0083] Step S43, selecting another initial atomization path, calculating the fitness value, comparing it with the fitness value calculated last time, and retaining the initial atomization path with a larger fitness value;

[0084] Step S44: perform iterative calculation and output the initial atomization path with the largest fitness value as the optimal atomization path.

[0085] After obtaining multiple initial atomization paths, it is necessary to optimize the initial atomization paths. The present invention adopts a sparrow search algorithm to perform optimization. After randomly selecting an initial atomization path, the fitness value of the sparrow is calculated. The calculation is based on the deposition efficiency being within the standard deposition efficiency range. After iterative calculation, the fitness value of each initial atomization path can be obtained. After a before-and-after comparison, the initial atomization path with the largest fitness value can be retained, and the initial atomization path is output as the optimal atomization path. The drug particle size in the optimal atomization path represents that when atomization treatment is performed, its deposition efficiency can meet the standard deposition efficiency range, so as to facilitate targeted treatment of users and improve the treatment effect.

[0086] Preferably, in step S5, when delivering the atomized drug to the user, the user's breathing frequency, inhalation depth and exhalation time are monitored in real time, and after updating the respiratory model based on the real-time monitoring data, the initial atomization path and the optimal atomization path are reacquired, and the atomization state is updated according to the drug particle size in the latest optimal atomization path.

[0087] When the user is receiving treatment based on the drug particle size in the optimal atomization path, the user's breathing status will be collected in real time, including breathing frequency, inhalation depth, and exhalation time, and then the drug particle size will be processed and adjusted in real time based on the breathing data to ensure that the best treatment plan is provided to the user.

[0088] Reference Figure 6 A system for monitoring the use of aerosolized medicine is shown, comprising:

[0089] A data acquisition unit 1 is used to acquire basic data of a user, and acquire a standard deposition efficiency range of the drug to be atomized based on the basic data;

[0090] A respiratory tract model building unit 2 is used to obtain the user's respiratory tract data and build a respiratory tract model according to the user's respiratory tract data;

[0091] The initial atomization path construction unit 3 is used to output the movement process of the atomized drugs with different particle sizes in the respiratory tract model as a plurality of initial atomization paths;

[0092] The optimization unit 4 is used to optimize the initial atomization path by using a sparrow search algorithm based on the deposition efficiency being within the standard deposition efficiency range, and obtain the optimal atomization path;

[0093] Atomization working unit 5, used for atomizing the atomized medicine based on the particle size of the atomized medicine in the optimal atomization path, and delivering the atomized medicine to the user;

[0094] The initial atomization path construction unit 3 is data-connected with the data acquisition unit 1 , the respiratory tract model construction unit 2 and the optimization unit 4 , respectively. The optimization unit 4 is data-connected with the data acquisition unit 1 and the atomization working unit 5 .

[0095] A system for monitoring the use of aerosolized drugs of the present invention monitors the entire process before and during the use of aerosolized drugs by a user, wherein a data acquisition unit 1 can collect basic data of the user, and search for a to-be-aerosolized drug for treating the user's disease based on the basic data of the user, and extract a standard deposition efficiency range from the instructions for use of the to-be-aerosolized drug, and the data collected by the data acquisition unit 1 will be sent to an initial aerosolization path construction unit 3 and an optimization unit 4, and a respiratory model construction unit 2 can construct a virtual respiratory model for the respiratory data of the user, for simulating the transport and deposition of the aerosolized drug in the respiratory tract of the user, and the constructed respiratory model will be sent to the initial aerosolization path construction unit 3 and the optimization unit 4. In the atomization path construction unit 3, the initial atomization path construction unit 3 divides the drug to be atomized into multiple particle sizes and then delivers them to the respiratory tract model. The respiratory tract model evolves the drug delivery process and records the drug delivery process of each particle size as the initial atomization path. The initial atomization path will be delivered to the optimization unit 4, and the optimization unit 4 will find the optimal atomization path therefrom. When the drug in the optimal atomization path is delivered in the respiratory tract, its deposition efficiency will meet the standard deposition efficiency range of the drug to be atomized. Finally, the atomization working unit 5 can extract the drug particle size in the optimal atomization path, and after atomizing the drug with the particle size, deliver it to the user for treatment, thereby achieving targeted drug deposition and improving the treatment effect.

[0096] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for monitoring the use of aerosolized drugs, characterized in that: The following steps are involved: Step S1, obtaining basic data of the user, and obtaining a standard deposition efficiency range of the drug to be atomized based on the basic data; Step S2: Acquire the user's respiratory tract data, and construct a respiratory tract model according to the user's respiratory tract data; Step S3, outputting the movement process of the to-be-atomized drugs of different particle sizes in the respiratory tract model as a plurality of initial atomization paths; Step S4, using a sparrow search algorithm to optimize the initial atomization path based on the deposition efficiency being within the standard deposition efficiency range, and obtaining the optimal atomization path; Step S5, atomizing the drug to be atomized based on the particle size of the drug to be atomized in the optimal atomization path, and delivering the drug to the user; The specific steps of step S4 include: Step S41, initializing the sparrow population, and setting the number of iterations to the number of initial atomization paths; Step S42, randomly selecting an initial atomization path, and calculating the fitness value of the sparrow based on the deposition efficiency being within the standard deposition efficiency range; Step S43, selecting another initial atomization path, calculating the fitness value, comparing it with the fitness value calculated last time, and retaining the initial atomization path with the larger fitness value; Step S44: perform iterative calculation and output the initial atomization path with the largest fitness value as the optimal atomization path.

2. A method for monitoring the use of aerosolized medicine according to claim 1, characterized in that: The specific steps of step S1 include: Step S11, extracting basic information of the user, the basic information including height, weight, age, medical history and allergy history; Step S12, obtaining the type of medicine to be atomized suitable for the user according to the basic information of the user; Step S13: obtaining a standard deposition efficiency range from the instructions for use of the drug to be atomized.

3. A method for monitoring the use of aerosolized medicine according to claim 2, characterized in that: When obtaining the type of medicine to be atomized, the step S12 inputs the basic information of the user into the trained deep learning network, which processes the information and obtains the type of medicine to be atomized suitable for the user.

4. A method for monitoring the use of aerosolized medicine according to claim 1, characterized in that: The specific steps of step S2 include: Step S21, obtaining a chest CT scan image of the user, preprocessing the CT scan image, and obtaining a respiratory tract tomographic anatomical image; Step S22, using three-dimensional reconstruction software to convert the anatomical image into a three-dimensional geometric model; Step S23, performing a pulmonary ventilation function test and a respiratory impedance test on the user, and constructing an airflow field model after collecting respiratory function data; Step S24: superimpose the airflow field model onto the three-dimensional geometric model to obtain a respiratory tract model.

5. A method for monitoring the use of aerosolized medicine according to claim 4, characterized in that: After obtaining the 3D geometric model, surface mesh simplification technology is used to reduce the number of faces and nodes of the 3D geometric model.

6. A method for monitoring the use of aerosolized medicine according to claim 1, characterized in that: The specific steps of step S3 include: Step S31, preliminarily determining the particle size range according to the physical and chemical properties of the drug to be atomized; Step S32, obtaining the atomizer device information to be used, and narrowing the particle size range based on the atomizer device information; Step S33, randomly selecting a particle size from the particle size range, and inputting the drug of the particle size into the respiratory tract model; Step S34, record the movement path of the drug in the respiratory tract model and output it as an initial atomization path, repeat steps S33-S34, and obtain several initial atomization paths.

7. A method for monitoring the use of aerosolized medicine according to claim 6, characterized in that: Before the drug moves in the respiratory tract model, the airflow drag, gravity and Brownian force are applied to the respiratory tract model, and the movement path of the drug in the respiratory tract model is recorded.

8. A method for monitoring the use of aerosolized medicine according to claim 1, characterized in that: In step S5, when delivering the atomized drug to the user, the user's breathing frequency, inhalation depth and exhalation time are monitored in real time, and the respiratory model is updated based on the real-time monitoring data, and the initial atomization path and the optimal atomization path are reacquired, and the atomization state is updated according to the drug particle size in the latest optimal atomization path.

9. A system using the method for monitoring the use of aerosolized medicine according to any one of claims 1 to 8, characterized in that: include: A data acquisition unit, used to acquire basic data of a user, and acquire a standard deposition efficiency range of the drug to be atomized based on the basic data; A respiratory tract model building unit, used to obtain the user's respiratory tract data and build a respiratory tract model according to the user's respiratory tract data; An initial atomization path construction unit is used to output the movement process of the atomized drugs with different particle sizes in the respiratory tract model as a number of initial atomization paths; An optimization unit, used for optimizing the initial atomization path by using a sparrow search algorithm based on the deposition efficiency being within a standard deposition efficiency range, and obtaining an optimal atomization path; An atomization working unit, used for atomizing the atomized medicine based on the particle size of the atomized medicine in the optimal atomization path and delivering the atomized medicine to the user; The initial atomization path construction unit is respectively connected with the data acquisition unit, the respiratory tract model construction unit and the optimization unit, and the optimization unit is respectively connected with the data acquisition unit and the atomization working unit.

Images